<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00668239</url>
  </required_header>
  <id_info>
    <org_study_id>HCPA-04288</org_study_id>
    <nct_id>NCT00668239</nct_id>
  </id_info>
  <brief_title>Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone or Laser</brief_title>
  <official_title>Treatment of Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone and Laser Photocoagulation: Randomized Clinical Trial With Morphological and Functional Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the use of intravitreous triamcinolone and laser therapy to treat
      maculopahty in patients with type 2 diabetes mellitus in a short-tem period of 6 months
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this double blind randomized clinical trial was to compare the treatment of
      diffuse diabetic macular oedema with intravitreal triamcinolone and laser in patients with
      type 2 diabetes mellitus (DM), using a morphofunctional assessment. Patients with clinically
      significant diffuse macular oedema, previously untreated and with a macular thickness &gt;250 μm
      at optical coherence tomography (OCT) were randomized for treatment with Laser or
      intravitreal injection of Triamcinolone acetate. Optical coherence tomography (OCT),
      biomicroscopy, fundoscopy, fluorescein angiography, tonometry, scotometry, visual acuity and
      contrast acuities were performed at 0, 1, 3 and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>diffuse macular oedema</measure>
    <time_frame>1, 3 and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>morphofunctional assessment of retina</measure>
    <time_frame>1,3 and 6 monts</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laser treatment: laser was applied to the macular region according to the modified grid technique in inverted C, preserving 500 μ of the foveolus and avascular zone, with 100μ diameter shots, energy varying from 0.2 to 0.5 joules, with a time of exposure between 0.2 and 0.4 seconds. One hundred and fifty to 200 shots were applied according to the size of the retinal area². ND YAG laser (Crystal Focus (EMERED®) was used</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>triamcinolone as previously described</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreous triamcinolone</intervention_name>
    <description>Intravenous injection of 0.1 ml (4 mg) of triamcinolone acetate was performed through the pars plana in a surgical environment. The medication used was manipulated by the Ophthalmos chemist. This type of formulation is different from the similar American one (Kenalog ®) since it does not use a conservation agent</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laser therapy</intervention_name>
    <description>pan fotocoaglulation by laser therapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with type 2 DM, diffuse macular oedema secondary to diabetic retinopathy,
             seen at the Centre of Reference for Diabetic Retinopathy at Hospital de Clinicas de
             Porto Alegre (HCPA) and at the Ophthalmology Outpatient Clinic at HCPA,

        Exclusion Criteria:

          -  patients with type 2 DM and previous treatment of diffuse macular oedema secondary to
             diabetic retinopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto L Gil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Health Science of Porto Alegre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90630040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOspital de Clínicas de Porto alegre</name>
      <address>
        <city>Porto alegre</city>
        <state>RS</state>
        <zip>9035/903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2008</study_first_posted>
  <last_update_submitted>April 28, 2008</last_update_submitted>
  <last_update_submitted_qc>April 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>MIrela Jobim de Azevedo</name_title>
    <organization>MIrela Jobim de Azevedo</organization>
  </responsible_party>
  <keyword>diffuse macular oedema</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>laser therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

